RUNX2 Antibodies

Structure of RUNX2

Myoglobin is a relatively small protein with a molecular weight of approximately 16.7 kDa. This weight may slightly vary between species due to minor differences in amino acid sequence.

The RUNX2 protein contains the N-terminal RUNX domain, the C-terminal transcriptional activation domain, and the nuclear localization signal. Its tertiary structure shows that the RUNX domain adopts a β -barrel folding mode and, after binding with the CBFβ cofactor to form a heterodimer, enhances the DNA binding ability. This protein regulates the transcription of target genes by specifically recognizing the core sequence 5'-ACCACA-3', and its C-terminal proline/serine/threonine enrichment region mediates the transcriptional activation function. This multi-domain synergy enables RUNX2 to precisely regulate the expression of genes related to osteoblast differentiation and bone development.

Fig. 1 The isoform view of human RUNX2.¹

Key structural properties of RUNX2:

• Contains a conserved Runt domain that mediates DNA binding
• The C-terminal transcriptional activation domain is rich in proline/serine/threonine
• Nuclear localization signals ensure the aggregation of proteins within the nucleus

Functions of RUNX2

The main function of the RUNX2 gene is to regulate bone development and osteoblast differentiation. In addition, it is also involved in a variety of biological processes, including cell fate determination and disease occurrence.

RUNX2 exerts transcriptional activation by binding to the ACCACA sequence in the promoter region of the target gene. Its activity is precisely regulated by multiple signaling pathways such as BMP/Smad and Wnt/β-catenin, playing a core role in maintaining bone homeostasis and pathological processes.

Applications of RUNX2 and RUNX2 Antibody in Literature

1. Lin, Tsung-Chieh. "RUNX2 and Cancer." International Journal of Molecular Sciences 24.8 (2023): 7001. https://doi.org/10.3390/ijms24087001

The article indicates that RUNX2, as a key transcription factor, not only regulates cell differentiation, but also its somatic mutations and expression characteristics are associated with the progression, metastasis and drug resistance of various cancers. It is regarded as a potential cancer biomarker. Recent studies have revealed its mechanism and clinical significance in tumorigenesis.

2. Komori, Toshihisa. "Regulation of skeletal development and maintenance by Runx2 and Sp7." International Journal of Molecular Sciences 25.18 (2024): 10102. https://doi.org/10.3390/ijms251810102

The article indicates that Runx2 is a core transcription factor in bone development. It regulates the orientation, proliferation and differentiation of mesenchymal cells towards the osteoblast lineage, and induces the expression of bone matrix protein genes. Runx2 interacts with multiple signaling pathways, such as Hedgehog and Wnt, and coordinates the osteogenesis process by inducing factors like Sp7. In addition, Runx2 is also an important pathogenic factor in osteoarthritis.

3. Gargalionis, Antonios N., et al. "Runx2 and polycystins in bone mechanotransduction: challenges for therapeutic opportunities." International Journal of Molecular Sciences 25.10 (2024): 5291. https://doi.org/10.3390/ijms25105291

The article indicates that Runx2 is a core molecule in bone mechanical conduction, regulated by mechanical stimuli and collaborating with factors such as polycystic proteins to dominate the process of bone remodeling and regeneration. Its targeting strategy provides a new direction for the treatment of bone loss diseases.

4. Błasiak, Janusz, Daniel Wysokiński, and Elżbieta Pawłowska. "Role of RUNX2 in Breast Carcinogenesis." International Journal of Molecular Sciences 16.9 (2015). https://doi.org/10.3390/ijms160920969

The article indicates that RUNX2 is not only a key factor for osteogenesis but also promotes the development of breast cancer by regulating DNA damage response, cell cycle and estrogen signaling pathways, especially closely related to the interaction between the Wnt/Tgfβ pathway and ERα, and can serve as a potential therapeutic target.

5. Wang, Cheng, et al. "Poly (ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2." Nature communications 10.1 (2019): 1203. https://doi.org/10.1038/s41467-019-09174-1

The article indicates that PARP1 activity increases in vascular calcification. It inhibits the expression of miR-204 through the IL-6/STAT3 pathway, reliefs the inhibition of Runx2, thereby promoting the expression of Runx2 protein and the transdifferentiation of vascular smooth muscle cells into osteogenic phenotypes, and intensifying calcium deposition.

Creative Biolabs: RUNX2 Antibodies for Research

Creative Biolabs specializes in the production of high-quality RUNX2 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom RUNX2 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our RUNX2 antibodies, custom preparations, or technical support, contact us at email.